Summary
- Closed for EoI
- Profile Type
- Research & Development Request
- POD Reference
- RDRCY20241017011
- Term of Validity
- 21 October 2024 - 21 October 2025
- Company's Country
- Cyprus
- Type of partnership
- Research and development cooperation agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- Cypriot company which specializes in personalized cancer therapy, leveraging AI and ML for innovative prognostic and diagnostic solutions. The company seeks research partnerships to expand the impact on cancer care patients through innovative research and development.
- Full Description
- The Cypriot-based company stands at the forefront of oncological research, pioneering the integration of ultrasound imaging with advanced AI and ML algorithms to redefine cancer prognosis and diagnosis. The unique approach of the company, not only enhances the accuracy of therapy responses but also facilitates the identification of viable biomarkers, significantly advancing personalized treatment strategies. The methodology allows for early intervention and tailored therapy plans, improving patient outcomes. The software capabilities of the company, include comprehensive statistical analysis tools such as t-tests and ANOVA, crucial for robust data analysis and validation in research environments. The company is actively looking to collaborate with academic and industry partners who are committed to transforming cancer treatment through innovative research and development.
- Stage of Development
- Available for demonstration
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- IPR description
-
Academic Institutions: For conducting joint research and development projects, sharing expertise in AI and ML applications in oncology, and accessing novel research facilities.
Medical Research Centers: To validate diagnostic and prognostic tools in clinical settings, collaborate on clinical trials, and develop new therapeutic protocols.
Biotechnology and Pharmaceutical Companies: To leverage their R&D capabilities in drug development and therapy personalization, integrating our AI solutions to enhance treatment outcomes.
Healthcare Providers: To implement and test technologies in real-world medical environments, providing feedback to refine our solutions.
Technology Development Companies: Specializing in medical devices and software, for technological collaboration and integration of advanced imaging and data analysis techniques.
Partner Sought
- Expected Role of a Partner
-
Academic Institutions: For conducting joint research and development projects, sharing expertise in AI and ML applications in oncology, and accessing novel research facilities.
Medical Research Centers: To validate diagnostic and prognostic tools in clinical settings, collaborate on clinical trials, and develop new therapeutic protocols.
Biotechnology and Pharmaceutical Companies: To leverage their R&D capabilities in drug development and therapy personalization, integrating our AI solutions to enhance treatment outcomes.
Healthcare Providers: To implement and test technologies in real-world medical environments, providing feedback to refine our solutions.
Technology Development Companies: Specializing in medical devices and software, for technological collaboration and integration of advanced imaging and data analysis techniques. - Type and Size of Partner
- SME <=10
- SME 50 - 249
- Big company
- R&D Institution
- SME 11-49
- University
- Type of partnership
- Research and development cooperation agreement
Call details
- Framework program
- Horizon Europe
- Call title and identifier
-
Call for Proposals on Personalised Cancer Medicine
EU4H-2024-PJ-03 - Anticipated project budget
-
€1.5 million
- Coordinator required
-
No
- Deadline for EoI
- Deadline of the call
- Project duration in weeks
-
104
- Web link to the call
- https://ec.europa.eu/info/funding-tenders/opportunities/portal/screen/opportuni…
- Project title and acronym
-
Title: Enhancing Personalized Cancer Treatment through AI-Driven Prediction (EPECT)
Acronym: AI-EPECT
- Horizon Europe
EU4H-2024-PJ-03
Acronym: AI-EPECT
Dissemination
- Technology keywords
- 06001005 - Diagnostics, Diagnosis
- 06001013 - Medical Technology / Biomedical Engineering
- Market keywords
- 05001001 - Diagnostic services
- 05003001 - Therapeutic services
- Sector Groups Involved
- Health
- Targeted countries
- All countries